-
Dec 6, 2024 | 
finewoodworking.com | David Fisher
Synopsis: David Fisher has designed a bowl that can be carved from a dry 8/4 board and worked on a standard workbench. In this article, he shares step-by-step instructions for crowning the top, laying out the handles and the hollow, carving the hollow, refining the hollow, creating the side curves, and shaping the underside. All the work is done with hand tools. In a separate Handwork piece, Fisher shares his technique for adding a decorative carved tree. No log, no axe, no problem.
-
Nov 15, 2024 | 
nature.com | Steven Horwitz |Ajit J Nirmal |Jahan A. Rahman |Ran Xu |Esther N. Drill |David Fisher | +7 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03076-6, published online 17 June 2024. In the version of this article initially published, there were two typographical errors in the SS (Sezary syndrome) row in the Arm A section of Table 3. The PRR (partial response rate) for both all patients and at MTD only should have been shown as “50 (2)” instead of “29 (2)” and “40 (2)”, respectively. The errors do not affect the conclusions of the study.
-
Nov 6, 2024 | 
onclive.com | David Fisher
CommentaryVideoNovember 6, 2024Author(s):David C. Fisher, MD, discusses pirtobrutinib resistance mechanisms that may develop during therapy in patients with CLL David C.
-
Oct 29, 2024 | 
onclive.com | David Fisher
David C. Fisher, MD, institute physician, Medical Oncology, Dana-Farber Cancer Institute; assistant professor of medicine, Harvard Medical School, discusses the integration of treatment with both CAR T-cell therapy and bispecific antibodies into the therapeutic landscape for patients with cytokine release syndrome (CRS).
-
Oct 23, 2024 | 
onclive.com | David Fisher
CommentaryVideoOctober 23, 2024Author(s):David C. Fisher, MD, discusses resistance mechanisms observed among patients with CLL who were previously treated with covalent BTK inhibitors. David C.
-
Jun 17, 2024 | 
nature.com | Steven Horwitz |Ajit J Nirmal |Jahan A. Rahman |Ran Xu |Esther N. Drill |David Fisher | +7 more
AbstractPI3K-δ inhibitors have shown impressive activity in lymphoid malignancies but have been hampered by autoimmune and infectious toxicities, leading to market withdrawals. We previously demonstrated activity of the PI3K-δγ inhibitor duvelisib in T cell lymphomas (TCLs) that was associated with inflammatory adverse events.
-
May 12, 2024 | 
nature.com | Thomas G. Hayhow |Rodrigo J. Carbajo |David Fisher |Frederick W. Goldberg |Lorna Hopcroft |Philip Hopcroft | +5 more
AbstractTargeting the estrogen receptor alpha (ERα) pathway is validated in the clinic as an effective means to treat ER+ breast cancers. Here we present the development of a VHL-targeting and orally bioavailable proteolysis-targeting chimera (PROTAC) degrader of ERα. In vitro studies with this PROTAC demonstrate excellent ERα degradation and ER antagonism in ER+ breast cancer cell lines. However, upon dosing the compound in vivo we observe an in vitro-in vivo disconnect.
-
Oct 17, 2023 | 
finewoodworking.com | David Fisher
ON-DEMAND COURSE AVAILABLE NOWUsing tools usually relegated to firewood preparation, David Fisher starts with a log and turns it into a bowl that’s refined and beautiful. Known as one of the masters of bowl carving in the greenwood movement, David has carved hundreds of them—and in this video workshop on carving a bowl, he will show you step-by-step the process he uses. This series is also available as part of a Fine Woodworking UNLIMITED membership. Already a member? Access here.
-
Sep 28, 2023 | 
onlinelibrary.wiley.com | Rebecca Turner |Tim Williams Band |Tim Morris |David Fisher
1 INTRODUCTION Network meta-analysis is an important and popular way to compare a number of treatments for a given condition (1). In a network meta-analysis, studies evaluating multiple treatment comparisons are modeled simultaneously, and estimation is based on a combination of direct and indirect evidence (2-6).
